Accordingly, SIRT1 ISGylation promoted lung cancer progression and limited lung cancer cell sensitivity to DNA damage-based therapeutics in in vivo and in vitro models, and elevated expression of SIRT1 and ISG15 was associated with poor prognosis in lung cancer patients. This evidence concerns the gene ISG15 and lung carcinoma.